In addition, in the view to reduce the sorafenib-mediated side effects and to maintain the efficiency of drug treatment, our findings provided a rationale for the use of the Akt inhibitor perifosine as an adjuvant with sorafenib in clinical trials of advanced BC. This evidence concerns the gene AKT1 and breast cancer.